Clinical trial
Pemetrexed and Carboplatin in Locally Advanced or Metastatic Breast Cancer
NCT00072865 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00072865 |
|---|---|
| Title | Pemetrexed and Carboplatin in Locally Advanced or Metastatic Breast Cancer |
| Official title | A Phase II Study of Alimta and Carboplatin in the Treatment of Patients With Locally Advanced or Metastatic Breast Cancer |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer, Neoplasm Metastasis |
| Intervention type | Drug |
| Interventions | Pemetrexed, Carboplatin |
| Enrollment | 50 |
| Start date | Jun 1, 2003 |
| Completion | Sep 1, 2005 |
| First posted | Nov 13, 2003 |
| Last update posted | Jan 26, 2007 |
| Countries | Russia |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: